Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women

Screening Inclusion Criteria: * Women 18-40 years of age at the time of screening * Willing to be screened for HSV-2 using a rapid, FDA approved test * Using an effective method of birth control (examples of effective methods of birth control are: women practicing abstinence x 90 days, hormonal birth control, consistent condom use, bilateral tubal ligation, partner with a vasectomy) Screening Exclusion Criteria: * Pregnant or nursing mother * Use of any antimicrobial agents (vaginal or systemic) for the treatment of any condition within 7 days * Presence of any intrauterine device * Allergy or hypersensitivity to valcyclovir or nucleoside analogues Enrollment Inclusion Criteria: * Women 18-40 Years of age at the time of screening * HSV-2 seropositive as determined by rapid HSV-2 testing * Using an effective method of birth control (examples of effective methods of birth control are: women practicing abstinence x 90 days, hormonal birth control, consistent condom use, bilateral tubal ligation, partner with a vasectomy) * Willing to avoid use of any intravaginal products during study period * Capable of providing written informed consent * Capable of cooperating to the extent and degree required by this protocol Enrollment Exclusion Criteria: * Pregnancy (all women will have a urine pregnancy test prior to randomization and treatment) * nursing mother * Menopausal women * Use of any antimicrobial agents (vaginal or systemic) for the treatment of any condition within 7 days of study enrollment * Known immunocompromised state * Significant Medical disorder that precludes accurate evaluation of participants condition * Presence of any intrauterine device * History of significant hepatic or renal impairment * Sensitivity/allergy to valacyclovir or nucleoside analogues * history of acyclovir or valacyclovir resistant HSV infection * Participation in a study using an investigational product in the past 30 days